<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004253</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067500</org_study_id>
    <secondary_id>BHM-L1</secondary_id>
    <secondary_id>BHM-99-64</secondary_id>
    <secondary_id>NCI-V99-1582</secondary_id>
    <nct_id>NCT00004253</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Phase II Study of 3-Dimensional Conformal Hyperfractionation Radiation Therapy (3D-CHRT) With Dose Escalation and Amifostine Mucosal Protection for Patients With Favorable Prognosis Inoperable Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving Paclitaxel and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Health South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Specialized radiation therapy delivers a high dose of radiation&#xD;
      directly to the tumor which may kill more tumor cells and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and&#xD;
      specialized high-dose radiation therapy in treating patients who have stage II or stage III&#xD;
      non-small cell lung cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the probability of overall survival and local control in patients with&#xD;
           favorable prognosis, unresectable stage II-IIIA/B non-small cell lung cancer receiving&#xD;
           paclitaxel and carboplatin plus 3-D conformal hyperfractionation radiotherapy (3D-CHRT).&#xD;
&#xD;
        -  Determine the incidence and severity of nonhematologic toxicity, specifically&#xD;
           esophagitis and pneumonitis, during 3D-CHRT and chemotherapy with paclitaxel and&#xD;
           carboplatin in these patients.&#xD;
&#xD;
        -  Correlate complication rate with radiation based on the effective dose to determine safe&#xD;
           treatment guidelines.&#xD;
&#xD;
        -  Determine the feasibility of patient-specific dose escalation using this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the quality of life and symptom distress in these patients on this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of 3-D conformal hyperfractionated radiotherapy&#xD;
      (3D-CHRT).&#xD;
&#xD;
      Patients receive paclitaxel IV over 1 hour followed immediately by carboplatin IV over 30&#xD;
      minutes weekly for 6-8 weeks. Patients undergo 3D-CHRT twice daily five days a week for 6-8&#xD;
      weeks.&#xD;
&#xD;
      Cohorts of patients receive escalating doses of 3D-CHRT in 4 dose levels.&#xD;
&#xD;
      Quality of life is assessed prior to study, weekly during chemotherapy and radiotherapy, and&#xD;
      at 3 and 6 months.&#xD;
&#xD;
      Patients are followed at 6 weeks, every 3 months for 1 year, every 6 months for 2 years and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 26-72 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patients with unresected locally advanced non-small cell lung cancer&#xD;
&#xD;
               -  Stage II, IIIA, or IIIB&#xD;
&#xD;
               -  No evidence of hematogenous metastases&#xD;
&#xD;
          -  No pleural effusion(s) on chest x-ray (except after a thoracotomy or other invasive&#xD;
             thoracic procedure)&#xD;
&#xD;
          -  No intrathoracic tumor recurrence following resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 2,000/mm3&#xD;
&#xD;
          -  Platelet count at least 130,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 1.5 times upper limit of normal (unless caused by documented&#xD;
             benign disease)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No active or symptomatic cardiac disease&#xD;
&#xD;
          -  No acute myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No angina&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
          -  Cardiac ejection fraction greater than 50%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 at least 1.25 L AND&#xD;
&#xD;
          -  DLCO at least 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight loss no greater than 5% within 3 months of diagnosis&#xD;
&#xD;
          -  No other prior malignancy within the past 3 years except nonmelanomatous skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior thoracic or neck radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre A. Abitbol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baptist Health South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sylvester Cancer Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>July 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

